Omnicell (OMCL) Upgraded to “Sell” by BidaskClub

BidaskClub upgraded shares of Omnicell (NASDAQ:OMCL) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Several other brokerages have also recently issued reports on OMCL. Oppenheimer reaffirmed a buy rating and issued a $55.00 target price on shares of Omnicell in a report on Tuesday, December 5th. Cantor Fitzgerald reaffirmed a buy rating and issued a $63.00 target price on shares of Omnicell in a report on Thursday, February 1st. Zacks Investment Research raised shares of Omnicell from a sell rating to a hold rating in a report on Friday, February 2nd. Piper Jaffray Companies lifted their target price on shares of Omnicell from $38.00 to $44.00 and gave the stock a neutral rating in a report on Friday, February 2nd. Finally, Craig Hallum cut shares of Omnicell from a buy rating to a hold rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. Omnicell has an average rating of Hold and a consensus target price of $56.14.

How to Become a New Pot Stock Millionaire

OMCL stock opened at $42.15 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.73 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1,634.70, a PE ratio of 82.65, a price-to-earnings-growth ratio of 3.48 and a beta of 0.75. Omnicell has a twelve month low of $38.00 and a twelve month high of $55.40.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million during the quarter, compared to analysts’ expectations of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.37 earnings per share. sell-side analysts predict that Omnicell will post 0.77 EPS for the current fiscal year.

In related news, Chairman Randall A. Lipps sold 8,186 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total transaction of $361,903.06. Following the completion of the sale, the chairman now directly owns 224,206 shares in the company, valued at $9,912,147.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary S. Petersmeyer sold 575 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $44.43, for a total transaction of $25,547.25. The disclosure for this sale can be found here. 3.77% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the business. Elkfork Partners LLC bought a new position in shares of Omnicell in the fourth quarter worth approximately $225,000. Xact Kapitalforvaltning AB bought a new position in shares of Omnicell in the fourth quarter worth approximately $244,000. Martin & Co. Inc. TN boosted its position in shares of Omnicell by 7.6% in the fourth quarter. Martin & Co. Inc. TN now owns 65,165 shares of the company’s stock worth $3,161,000 after purchasing an additional 4,600 shares during the period. Pier Capital LLC boosted its position in shares of Omnicell by 9.6% in the fourth quarter. Pier Capital LLC now owns 117,875 shares of the company’s stock worth $5,717,000 after purchasing an additional 10,363 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Omnicell in the fourth quarter worth approximately $812,000.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3299031/omnicell-omcl-upgraded-to-sell-by-bidaskclub.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Flowers Foods  Lowered to Hold at Zacks Investment Research
Flowers Foods Lowered to Hold at Zacks Investment Research
Geopark  Upgraded to “Buy” at Zacks Investment Research
Geopark Upgraded to “Buy” at Zacks Investment Research
Marten Transport  Upgraded to “Strong-Buy” by BidaskClub
Marten Transport Upgraded to “Strong-Buy” by BidaskClub
James River Group  Downgraded to “Sell” at BidaskClub
James River Group Downgraded to “Sell” at BidaskClub
Analysts Expect First Community Co.  Will Post Earnings of $0.36 Per Share
Analysts Expect First Community Co. Will Post Earnings of $0.36 Per Share
Tenneco Inc  Receives $64.40 Consensus Target Price from Analysts
Tenneco Inc Receives $64.40 Consensus Target Price from Analysts


© 2006-2018 Ticker Report. Google+.